<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Probiotics for induction of remission in ulcerative colitis - Kaur, L - 2020 | Cochrane Library</title> <meta content="Probiotics for induction of remission in ulcerative colitis - Kaur, L - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005573.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Probiotics for induction of remission in ulcerative colitis - Kaur, L - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005573.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005573.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Probiotics for induction of remission in ulcerative colitis" name="citation_title"/> <meta content="Lakhbir Kaur" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Patricia Anne Baines" name="citation_author"/> <meta content="Zipporah Iheozor-Ejiofor" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Vasiliki Sinopoulou" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="aakobeng@sidra.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD005573.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005573.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005573.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005573.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [adverse effects, therapeutic use]; Bias; Colitis, Ulcerative [*therapy]; Combined Modality Therapy [methods]; Mesalamine [adverse effects, therapeutic use]; Numbers Needed To Treat; Probiotics [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Sample Size; Sulfasalazine [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005573.pub3&amp;doi=10.1002/14651858.CD005573.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005573\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005573\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005573.pub3",title:"Probiotics for induction of remission in ulcerative colitis",firstPublishedDate:"Mar 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005573.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005573.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005573.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005573.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005573.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005573.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005573.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005573.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005573.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005573.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8916 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005573.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/appendices#CD005573-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/table_n/CD005573StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/table_n/CD005573StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Probiotics for induction of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0004">Lakhbir Kaur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0005">Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0006">Patricia Anne Baines</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0007">Zipporah Iheozor-Ejiofor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0008">Vasiliki Sinopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information#CD005573-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Anthony K Akobeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information/en#CD005573-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005573.pub3">https://doi.org/10.1002/14651858.CD005573.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005573-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005573-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005573-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005573-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005573-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005573-abs-0001" lang="en"> <section id="CD005573-sec-0001"> <h3 class="title" id="CD005573-sec-0001">Background</h3> <p>Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not respond to first‐ or second‐line therapies. There is a significant proportion of people who experience adverse effects with current therapies. Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought. Probiotics are live microbial feed supplements that may beneficially affect the host by improving intestinal microbial balance, enhancing gut barrier function and improving local immune response. </p> </section> <section id="CD005573-sec-0002"> <h3 class="title" id="CD005573-sec-0002">Objectives</h3> <p>To assess the efficacy of probiotics compared with placebo or standard medical treatment (5‐aminosalicylates, sulphasalazine or corticosteroids) for the induction of remission in people with active ulcerative colitis. </p> </section> <section id="CD005573-sec-0003"> <h3 class="title" id="CD005573-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and two other databases on 31 October 2019. We contacted authors of relevant studies and manufacturers of probiotics regarding ongoing or unpublished trials that may be relevant to the review, and we searched ClinicalTrials.gov. We also searched references of trials for any additional trials. </p> </section> <section id="CD005573-sec-0004"> <h3 class="title" id="CD005573-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) investigating the effectiveness of probiotics compared to standard treatments or placebo in the induction of remission of active ulcerative colitis. We considered both adults and children, with studies reporting outcomes of clinical, endoscopic, histologic or surgical remission as defined by study authors </p> </section> <section id="CD005573-sec-0005"> <h3 class="title" id="CD005573-sec-0005">Data collection and analysis</h3> <p>Two review authors independently conducted data extraction and 'Risk of bias' assessment of included studies. We analysed data using Review Manager 5. We expressed dichotomous and continuous outcomes as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). We assessed the certainty of the evidence using the GRADE methodology. </p> </section> <section id="CD005573-sec-0006"> <h3 class="title" id="CD005573-sec-0006">Main results</h3> <p>In this review, we included 14 studies (865 randomised participants) that met the inclusion criteria. Twelve of the studies looked at adult participants and two studies looked at paediatric participants with mild to moderate ulcerative colitis, the average age was between 12.5 and 47.7 years. The studies compared probiotics to placebo, probiotics to 5‐ASA and a combination of probiotics plus 5‐ASA compared to 5‐ASA alone. Seven studies used a single probiotic strain and seven used a mixture of strains. The studies ranged from two weeks to 52 weeks. The risk of bias was high for all except two studies due to allocation concealment, blinding of participants, incomplete reports of outcome data and selective reporting. This led to GRADE ratings of the evidence ranging from moderate to very low. </p> <p><b>Probiotics versus placebo</b><br/>Probiotics may induce clinical remission when compared to placebo (RR 1.73, 95% CI 1.19 to 2.54; 9 studies, 594 participants; low‐certainty evidence; downgraded due to imprecision and risk of bias, number needed to treat for an additional beneficial outcome (NNTB) 5). Probiotics may lead to an improvement in clinical disease scores (RR 2.29, 95% CI 1.13 to 4.63; 2 studies, 54 participants; downgraded due to risk of bias and imprecision). </p> <p>There may be little or no difference in minor adverse events, but the evidence is of very low certainty (RR 1.04, 95% CI 0.42 to 2.59; 7 studies, 520 participants). Reported adverse events included abdominal bloating and discomfort. Probiotics did not lead to any serious adverse events in any of the seven studies that reported on it, however five adverse events were reported in the placebo arm of one study (RR 0.09, CI 0.01 to 1.66; 1 study, 526 participants; very low‐certainty evidence; downgraded due to high risk of bias and imprecision). Probiotics may make little or no difference to withdrawals due to adverse events (RR 0.85, 95% CI 0.42 to 1.72; 4 studies, 401 participants; low‐certainty evidence). </p> <p><b>Probiotics versus 5‐ASA</b><br/>There may be little or no difference in the induction of remission with probiotics when compared to 5‐ASA (RR 0.92, 95% CI 0.73 to 1.16; 1 study, 116 participants; low‐certainty evidence; downgraded due to risk of bias and imprecision). There may be little or no difference in minor adverse events, but the evidence is of very low certainty (RR 1.33, 95% CI 0.53 to 3.33; 1 study, 116 participants). Reported adverse events included abdominal pain, nausea, headache and mouth ulcers. There were no serious adverse events with probiotics, however perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema were reported in the 5‐ASA arm (RR 0.21, 95% CI 0.01 to 4.22; 1 study, 116 participants; very low‐certainty evidence). </p> <p><b>Probiotics combined with 5‐ASA versus 5‐ASA alone</b><br/>Low‐certainty evidence from a single study shows that when combined with 5‐ASA, probiotics may slightly improve the induction of remission (based on the Sunderland disease activity index) compared to 5‐ASA alone (RR 1.22 CI 1.01 to 1.47; 1 study, 84 participants; low‐certainty evidence; downgraded due to unclear risk of bias and imprecision). No information about adverse events was reported. </p> <p>Time to remission, histological and biochemical outcomes were sparsely reported in the studies. None of the other secondary outcomes (progression to surgery, need for additional therapy, quality of life scores, or steroid withdrawal) were reported in any of the studies. </p> </section> <section id="CD005573-sec-0007"> <h3 class="title" id="CD005573-sec-0007">Authors' conclusions</h3> <p>Low‐certainty evidence suggests that probiotics may induce clinical remission in active ulcerative colitis when compared to placebo. There may be little or no difference in clinical remission with probiotics alone compared to 5‐ASA. There is limited evidence from a single study which failed to provide a definition of remission, that probiotics may slightly improve the induction of remission when used in combination with 5‐ASA. There was no evidence to assess whether probiotics are effective in people with severe and more extensive disease, or if specific preparations are superior to others. Further targeted and appropriately designed RCTs are needed to address the gaps in the evidence base. In particular, appropriate powering of studies and the use of standardised participant groups and outcome measures in line with the wider field are needed, as well as reporting to minimise risk of bias. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005573-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005573-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005573-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005573-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005573-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005573-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005573-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005573-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005573-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005573-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005573-abs-0002" lang="en"> <h3>Probiotics for the treatment of active ulcerative colitis</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out whether probiotics can induce remission in people with ulcerative colitis. We analysed data from 14 studies to answer this question. </p> <p><b>Key messages</b> </p> <p>Probiotics may be better at inducing remission than placebo (dummy treatment). It is unclear whether probiotics are better than 5‐aminosalicylic acid (5‐ASA, an anti‐inflammatory agent used to treat inflammatory bowel disease), however there is limited evidence that when both treatments are used as combined therapy they may be better than 5‐ASA alone in inducing remission. Most studies reported that no serious adverse events took place. For the studies that did report on it, serious adverse events did not occur in the probiotic group. Minor adverse events reported were bloating and diarrhoea. </p> <p><b>What was studied in the review?</b> </p> <p>Ulcerative colitis is a relapsing and remitting disease which causes inflammation of the large bowel and leads to symptoms such as abdominal pain, diarrhoea and tiredness. There is some evidence to suggest that an imbalance in the bacteria of the gut is the cause of the disease, and therefore probiotics, which are live micro‐organisms, can alter the bacteria and possibly reduce the inflammation. </p> <p><b>What are the main results of the review?</b> </p> <p>We searched for randomised controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment groups) comparing probiotics with placebo, probiotics with 5‐ASA, and probiotics in combination with 5‐ASA. We found 14 RCTs looking at 865 participants. The trials looked at adult and paediatric participants. Eight studies allowed additional therapy to continue, whilst the other four studies were unclear about this. </p> <p>1) Probiotics may improve induction of clinical remission when compared to placebo.</p> <p>2) It is unclear whether probiotics lead to a difference in adverse events (minor and serious) when compared to placebo. </p> <p>3) There is limited evidence to determine whether probiotics offer better disease improvement when compared to placebo. </p> <p>4) There may be little or no difference in the induction of remission with probiotics when compared to 5‐ASA (low‐certainty evidence). </p> <p>5) There is limited evidence to suggest that when probiotics plus 5‐ASA are compared to 5‐ASA alone, probiotics may offer a slightly better chance of induction of remission. This is based on low‐certainty evidence from one study, and we are not sure of the type of remission studied. </p> <p>6) Serious adverse events were reported when probiotics were compared with placebo, but only occurred in the placebo group. </p> <p><b>Conclusion</b> </p> <p>Whilst the evidence suggests that probiotics may be better at improving induction than placebo, our confidence in the estimate is limited because of the low‐certainty evidence. This is attributed to the small number of participants in each study along with the unreliable methods utilised by the trials. With the evidence presented in these studies, we are unable to make strong conclusions into the effectiveness of probiotics; better designed studies with more participants are needed. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is up‐to‐date as of October 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005573-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005573-sec-0106"></div> <h3 class="title" id="CD005573-sec-0107">Implications for practice</h3> <section id="CD005573-sec-0107"> <p>There is low‐certainty evidence that probiotics may induce clinical remission in active ulcerative colitis compared to placebo, with a number needed to treat for an additional beneficial outcome of 5. The certainty of the evidence means that the true effect may be substantially different from the estimate of the effect, and future research may therefore change this finding. This is due to the flaws in reporting of studies and the inclusion of inadequate numbers of study participants. There may be little or no difference in the effects of probiotics alone compared with 5‐aminosalicylic acid (5‐ASA), due to very low‐certainty evidence. There is limited evidence from a single study which failed to provide a definition of remission, that probiotics may confer a small added benefit in inducing remission when combined with 5‐ASA, over 5‐ASA alone. There is no clear difference in withdrawals due to adverse events between probiotics and placebo. This is also based on low‐certainty evidence. Minor and serious adverse events were poorly reported (very low‐certainty evidence). The applicability of the evidence in clinical practice is limited due to the heterogenous studies and this is reflected in the low to very low rating in certainty of the evidence. Commonly reported minor adverse events were abdominal bloating and discomfort. None of the studies reported any serious adverse events with probiotics. </p> </section> <h3 class="title" id="CD005573-sec-0108">Implications for research</h3> <section id="CD005573-sec-0108"> <p>This review highlights the need for further research in this area that targets relevant clinical questions, uses appropriate and improved trial procedures, and reports in a manner that will allow future integration with this current evidence base to produce the clearer answers clinicians and patients require. There is only one trial ongoing. </p> <p>In terms of trial quality, first the conception of trials must be considered. Eight studies had compared probiotics to placebo, which is not representative of current clinical practice, where patients will be on standard therapy to aid being induced. Therefore, it would be more suited for studies to compare probiotics plus standard care versus standard care alone, or indeed three‐armed trials. </p> <p>The question of sample size is also a major concern, as stated above. The effect sizes reported in this review should form an appropriate source of data for future power calculations, and allow suitable sample sizes to be recruited. </p> <p>As there is some limited evidence from a single trial of probiotics added to 5‐ASA therapy conferring a benefit when compared to 5‐ASA alone, this may form a natural foundation for future investigation. </p> <p>The length of the studies were variable, and the time to relapse was not reported in most studies, and again these are key pragmatic questions that will support decision making from such trial data. Future studies should also consider whether they will also measure the rates of longer‐term relapse after initial induction. However, if they choose to do this, suitably lengthy follow‐up times must be used. </p> <p>Adverse events were capriciously reported amongst the studies, which was a concern with our service user author. Given that the class of agent can be directly available to patients, it is important for their safety and autonomy that adverse events are graded as minor and severe, and defined in the study to aid future systematic reviews, and allow patients to make informed decisions if they choose to obtain the agent independently. </p> <p>Studies should also consider the effects of different probiotics, different dosing regimens and specific patient subgroups, for example patients with severe disease who may benefit from probiotic treatment or children. </p> <p>Service user involvement in the review process has brought to the forefront key issues, which are important to patients and need to be taken into account in future research. As probiotics can be available both as prescribed medical agents and food supplements direct to patients, both cohorts are recognised in the studies included. Future research may wish to explicitly state the local status of studied products as this has implications for patients in terms of availability and autonomy in considering the potential role of probiotics, in addition to efficacy and safety concerns. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005573-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005573-sec-0008"></div> <div class="table" id="CD005573-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to placebo for induction of remission in ulcerative colitis (follow‐up 2 to 52 weeks)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/>(1.19 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>594<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was defined as the absence of rectal bleeding, a rectal mucosa without erythaema, granularity, or friability and normal or near‐normal sigmoidoscopic findings (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>); clinical DAI ≤ 2 (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>); occurrence or worsening of symptoms, accompanied by an increase in LCAI &gt; 3, sufficient to require treatment with corticosteroids, azathioprine/immunosuppressive agents or surgery (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>); final DAI score &lt; 2 (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>); UCDAI scores of 0‐2 (<a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>); UCDAI score &lt; 2 (<a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>); not having more than three well‐formed stools per day and without visible blood in the stools and any clinical symptoms of ulcerative colitis and had a clinical activity index &lt; 4 (<a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>); remission was based on UCDAI, however, no further information was provided (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>), bloody diarrhoea, without tachycardia, without fever, without anaemia and normal ESR and/or CRP (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>436 per 1000<br/>(300 to 640) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease improvement (based on clinical scores)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.29<br/>(1.13 to 4.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>54<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional RCT (144 participants) showed that probiotics improved disease based on endoscopic scores (RR 1.45, 95% CI 1.03 to 2.05). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>594 per 1000<br/>(249 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.42 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>520<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events reported were gastrointestinal disorders, unpleasant taste in the mouth, dizziness, flu‐like symptoms, acne, alopecia and dyspepsia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/>(56 to 345) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.09<br/>(0.01 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>526<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Aggravated proctosigmoiditis was reported in the placebo group in one study as the only adverse event. No other study provided further details. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.42 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>401<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study provided details on the adverse events leading to withdrawal from trial.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(66 to 268) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; CRP: c‐reactive protein; DAI; disease activity index; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; UCDAI: ulcerative colitis disease activity index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for high risk of bias in most of the studies and serious imprecision due to sparse data. We did not downgrade for inconsistency (substantial heterogeneity, I<sup>2</sup> = 66%) as effect estimates were fairly consistent across studies and heterogeneity was attributed to the differences in probiotic preparation.<br/><sup>2b</sup>Downgraded three times for risk of bias, very serious inconsistency (substantial heterogeneity, I<sup>2</sup> = 69%) and very serious imprecision due to CIs which include a risk of benefit and harm.<br/><sup>c</sup>Downgraded three times for risk of bias and very serious imprecision as CI includes a risk of benefit and harm.<br/><sup>d</sup>Downgraded two times for very serious imprecision as CI includes a risk of benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005573-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic compared to 5‐ASA for induction of remission in ulcerative colitis (52 weeks follow‐up; one study unclear)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospitals <br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.73 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was defined as general well‐being with the passage of no more than three formed stools per day, a rectal mucosa without erythaema, granularity or friability as well as histological confirmation. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>746 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000<br/>(544 to 865) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1,23</p> <p>(0.56 to 2.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>192<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events were abdominal pain, nausea, headache and mouth ulcer.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000 (63 to 395)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21</p> <p>(0.01 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events reported were perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> <p>(0 to 143)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21</p> <p>(0.01 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawals were due to perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> <p>(0 to 143)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylates; <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for risk of other bias (participants were classified according to disease severity and given specific concomitant treatments based on this classification, this puts the randomisation into question) and serious imprecision due to small sample size in a single study.<br/><sup>b</sup> Downgraded two times for risk of other bias; (participants were classified according to disease severity and given specific concomitant treatments based on this classification, this puts the randomisation into question) and once due to serious imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005573-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics plus 5‐ASA compared to 5‐ASA for induction of remission in ulcerative colitis (follow‐up 4 weeks to 24 months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotic plus 5‐ASA<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic plus 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/>(1.01 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was assessed based on the Sunderland activity score</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>930 per 1000<br/>(770 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for unclear risk of bias in most domains and serious imprecision due to small sample size in a single study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005573-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005573-sec-0009"></div> <section id="CD005573-sec-0010"> <h3 class="title" id="CD005573-sec-0010">Description of the condition</h3> <p>Ulcerative colitis is a chronic relapsing disease, with the greatest reported incidence in mainland Europe and Scandinavia of 9.2 to 20.3 per 100,000 people (<a href="./references#CD005573-bbs2-0045" title="Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology2004;126(6):1504-17. [PMID: 15168363]">Loftus 2004</a>), totalling approximately 2.2 million sufferers in Europe alone. The peak incidence of the disease occurs between 15 and 25 years of age and there is another smaller prevalence at ages 55 to 65. The disease is characterised by abdominal pain, bloody diarrhoea and faecal urgency. The diagnosis of ulcerative colitis is made on the basis of medical history, signs and symptoms, and any endoscopic or histopathological findings. </p> <p>The disease is caused by diffuse inflammation, which starts at the rectum, spreads proximally, and is limited to the colon. The aetiology of the disease is unknown, but is likely to be multifactorial; consisting of a genetic predisposition, dysregulation of the mucosal and epithelial barrier and lastly dysbiosis, although whether dysbiosis causes or is a result of the disease remains unclear (<a href="./references#CD005573-bbs2-0058" title="UngaroR , MehandruS , AllenPB , Peyrin-BirouletL , Colombel J-F. Ulcerative Colitis. Lancet2017;389(10080):1756-70.">Ungaro 2016</a>). The genetic predisposition creates a four‐fold risk for first‐degree relatives. </p> </section> <section id="CD005573-sec-0011"> <h3 class="title" id="CD005573-sec-0011">Description of the intervention</h3> <p>Probiotics are live micro‐organisms, that when consumed, may provide multiple health benefits. They produce their benefits by altering the gut microbiome through either enhancing the activity, volume or both, of the normal flora. <i>Lactobacillus spp</i>, for example, is one of the more popular probiotics and is thought to secrete bacteriocin, blocking the adherence or translocation of harmful bacteria (<a href="./references#CD005573-bbs2-0050" title="PanigrahiP . Probiotics and prebiotics in neonatal necrotizing enterocolitis: New opportunities for translational research. Pathophysiology2014;21(1):35-46.">Panigrahi 2014</a>). </p> <p><i>Lactobacillus rhamnosus GG</i> (<i>L</i> <i>rhamnosus GG</i>) produced mixed responses in animal models of colitis (<a href="./references#CD005573-bbs2-0036" title="DielemanLA , GoerresMS , ArendsA , SprengersD , TorriceC , HoentjenF , et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut2003;53(3):370-6.">Dieleman 2003</a>; <a href="./references#CD005573-bbs2-0055" title="ShiboletO , KarmeliF , EliakimR , SwennenE , BrigidiP , GionchettiP , et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases2002;8(6):399-406.">Shibolet 2002</a>), as did <i>Lactobacillus plantarum</i> (<i>L plantarum</i>) 299V (<a href="./references#CD005573-bbs2-0036" title="DielemanLA , GoerresMS , ArendsA , SprengersD , TorriceC , HoentjenF , et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut2003;53(3):370-6.">Dieleman 2003</a>; <a href="./references#CD005573-bbs2-0042" title="KennedyRJ , HoperM , DeodharK , KirkSJ , GardinerKR . Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scandinavian Journal of Gastroenterology2000;35(12):1266-71.">Kennedy 2000</a>; <a href="./references#CD005573-bbs2-0053" title="SchultzM , VeltkampC , DielemanLA , GrentherWB , WyrickPB , TonkonogySL , et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases2002;8(2):71-80.">Schultz 2002</a>). Studies investigating combinations of probiotic species incorporated within the probiotic De Simone Formulation have demonstrated a partial reduction of colitis in animal models (<a href="./references#CD005573-bbs2-0047" title="MadsenK , CornishA , SoperP , McKaigneyC , JijonH , YachimecC , et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology2001;121(3):580-91.">Madsen 2001</a>; <a href="./references#CD005573-bbs2-0055" title="ShiboletO , KarmeliF , EliakimR , SwennenE , BrigidiP , GionchettiP , et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases2002;8(6):399-406.">Shibolet 2002</a>). There has been increasing interest in the use of probiotics, as they are considered safe and easily accessible (<a href="./references#CD005573-bbs2-0049" title="OngTG , GordonM , BanksSS , ThomasMR , AkobengAK . Probiotics to prevent infantile colic. Cochrane Database of Systematic Reviews2019, Issue 3. [DOI: 10.1002/14651858.CD012473.pub2]">Ong 2019</a>). It is worth noting that there are a huge number of different preparations available, varying in the specific strains isolated, the use of mixed strains in a single preparation, the form of the preparation and finally the licensing arrangements surrounding the preparations (medicinal versus food products). </p> </section> <section id="CD005573-sec-0012"> <h3 class="title" id="CD005573-sec-0012">How the intervention might work</h3> <p>There is growing evidence looking at the effects of probiotics in the use of inducing remission in ulcerative colitis since a previous Cochrane review (<a href="./references#CD005573-bbs2-0061" title="MallonPT , McKayD , KirkSJ , GardinerK . Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005573]">Mallon 2007</a>). Due to the part that dysbiosis plays in ulcerative colitis, there is potential benefit in trying to restore the indigenous flora. Several observations, both on humans and animal models, emphasised the importance of bacterial flora in inflammatory bowel disease pathogenesis, justifying the current interest in antibiotic and probiotic therapies, aimed at the manipulation of enteric flora (<a href="./references#CD005573-bbs2-0035" title="CuiHH , ChenCL , WangJD , YangYJ , CunY , WuJB , et al. Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology2004;10(10):1521-5.">Cui 2004</a>). The therapeutic efficacy of probiotics has been demonstrated in various models of experimental colitis, including interleukin‐10 deficient mice (<a href="./references#CD005573-bbs2-0046" title="MadsenKL , DoyleJS , JewellLD , TaverniniMM , FedorakRN . Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology1999;116(5):1107-14.">Madsen 1999</a>; <a href="./references#CD005573-bbs2-0053" title="SchultzM , VeltkampC , DielemanLA , GrentherWB , WyrickPB , TonkonogySL , et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases2002;8(2):71-80.">Schultz 2002</a>), and acetic acid‐induced colitis in rats (<a href="./references#CD005573-bbs2-0038" title="FabiaR , Ar'RajabA , JohannssonML , WillenR , AnderssonR , MolinG , et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scandinavian Journal of Gastroenterology1993;28(2):155-62.">Fabia 1993</a>). </p> </section> <section id="CD005573-sec-0013"> <h3 class="title" id="CD005573-sec-0013">Why it is important to do this review</h3> <p>In the UK, National Institute for Health and Care Excellence (NICE) and USA guidelines state that first‐line therapy for maintenance of remission in ulcerative colitis is 5‐aminosalicylic acid (5‐ASA) (<a href="./references#CD005573-bbs2-0048" title="National Institute for Health and Care Excellence. Ulcerative Colitis Mangagement in adults, children and Young people CG166. NICE2013. [https://www.nice.org.uk/guidance/ng130/evidence/june-2013-full-guideline-pdf-6777262190]">NICE 2013</a>). 5‐ASA works by binding to PPAR‐ỿ and reducing cytokine production. Some of the adverse effects associated with 5‐ASA include headache, rash, nausea (common), pancreatitis (uncommon), and agranulocytosis (rare). Due to these side effects, some people are unable to tolerate the drug. If 5‐ASA fails to provide any relief then steroids can be added as an adjunct. Steroids, such as prednisolone, can also be used alone, however if after two to four weeks an adequate response is not observed, then immune suppressant therapies, such as anti‐tumour necrosis factor (TNF) monoclonals, vedolizumab and tofacitinib may be used to induce remission. These drugs work by blocking leukocyte recruitment at the molecular and vascular level (<a href="./references#CD005573-bbs2-0039" title="FiorinoG . The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therapeutic Advances in Gastroenerology2016;9(4):503-12.">Fiorino 2016</a>), some of the side effects include headache, dizziness and arthralgia. Despite these medications, failure to induce remission occurs in 20% to 30% of people on current treatments, with a proportion of patients eventually requiring colectomy. Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought. </p> <p>The relapsing and remitting nature of the disease means that people can be in and out of hospital, experimenting with different drug regimens. The treatment costs Europe between GBP 11 to 26 billion annually, with per patient costs approximately GBP 8011 to 9306 (<a href="./references#CD005573-bbs2-0033" title="CohenRD . Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmaology and Therapeutics2010;31(7):693-707.">Cohen 2010</a>). If an alternative, cheaper treatment can be found for ulcerative colitis, then it would greatly benefit not only a budget stricken National Health Service (NHS), but also improve patients' quality of life. Whilst some studies have suggested that probiotics may be useful for maintenance of remission in mild to moderate ulcerative colitis (<a href="./references#CD005573-bbs2-0044" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23.">Kruis 2004</a>; <a href="./references#CD005573-bbs2-0059" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74.">Zocco 2006</a>), others have failed to show any benefit (<a href="./references#CD005573-bbs2-0043" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8.">Kruis 1997</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>). The previous published form of this review is more than 10 years old (<a href="./references#CD005573-bbs2-0061" title="MallonPT , McKayD , KirkSJ , GardinerK . Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005573]">Mallon 2007</a>), and did not consider a paediatric population. As the burden of ulcerative colitis is shared within this population as well, consideration of studies in this group of patients would provide a greater understanding as to whether the intervention works differently in adults compared to children. In this review, we investigated the available evidence on the use of probiotics for the induction of remission in ulcerative colitis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005573-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005573-sec-0014"></div> <p>To assess the efficacy of probiotics compared with placebo or standard medical treatment (5‐aminosalicylic acid (5‐ASA), sulphasalazine or corticosteroids) for the induction of remission in people with active ulcerative colitis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005573-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005573-sec-0015"></div> <section id="CD005573-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005573-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD005573-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of any age with active ulcerative colitis previously diagnosed by clinical, endoscopic, histologic or surgical remissionas defined by study authors </p> </section> <section id="CD005573-sec-0019"> <h4 class="title">Types of interventions</h4> <p>RCTs comparing probiotics administered in any form (drink, powder, capsule) orally as a single species or as a cocktail of multiple species,versus placebo, probiotics standard therapy (e.g. 5‐aminosalicylic acid (5‐ASA), sulfasalazine or corticosteroids), or probiotics used in conjunction with standard therapy versus standard therapy for the induction of remission in active ulcerative colitis. </p> </section> <section id="CD005573-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD005573-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005573-list-0001"> <li> <p>Remission (clinical, endoscopic, histologic or surgical remission, as defined by study authors) </p> </li> </ul> </p> </section> <section id="CD005573-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005573-list-0002"> <li> <p>Disease improvement (clinical or endoscopic, as defined by study authors)</p> </li> <li> <p>Steroid withdrawal</p> </li> <li> <p>Clinical activity scores</p> </li> <li> <p>Histology scores</p> </li> <li> <p>Biochemical markers of inflammation</p> </li> <li> <p>Need for additional therapy</p> </li> <li> <p>Progression to surgery</p> </li> <li> <p>Symptomatic severity (stool frequency, abdominal pain)</p> </li> <li> <p>Quality of life scores</p> </li> <li> <p>Time to remission/improvement</p> </li> <li> <p>Minor adverse events</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Withdrawal due to adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD005573-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies regardless of language or publication status. </p> <section id="CD005573-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive and systematic search to identify RCTs from inception to 31 October 2019, using the following databases. </p> <p> <ul id="CD005573-list-0003"> <li> <p>Cochrane Inflammatory Bowel Disease Group Specialized Trials Register</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>MEDLINE</p> </li> <li> <p>Embase</p> </li> <li> <p>CINAHL</p> </li> </ul> </p> <p>We did not place restrictions on publication dates (after 1966) or language. We reported the detailed search strategies in <a href="./appendices#CD005573-sec-0112">Appendix 1</a>. </p> </section> <section id="CD005573-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We inspected the reference lists of all identified studies for additional trials. We also contacted leaders in the field and manufacturers of probiotics to identify potentially relevant studies. We also searched ClinicalTrials.gov for ongoing trials (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </section> </section> <section id="CD005573-sec-0026"> <h3 class="title" id="CD005573-sec-0026">Data collection and analysis</h3> <section id="CD005573-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We undertook study selection in <a href="./references#CD005573-bbs2-0034" title="Veritas Health InnovationCovidence. Version accessed prior to 4 February 2020. Melbourne, Australia: Veritas Health Innovation.Available at covidence.org.">Covidence</a>. </p> <p>Using the above search strategy, two review authors (LK, MG) identified titles that appeared to be potentially relevant. These were independently screened and in circumstances of disagreement, a third review author (AA) was involved to reach consensus. </p> <p>There is some evidence that data from abstract publications can be inconsistent with data from published articles (<a href="./references#CD005573-bbs2-0051" title="PitkinRM , BranaganMA , BurmeisterLF . Accuracy of data in abstracts of published research articles. JAMA1999;281:1110-1.">Pitkin 1999</a>), therefore we considered abstract publications, but only if sufficient data were presented to judge inclusion criteria fully and reports of the primary and secondary outcomes were given. If these were not available, we contacted authors directly, and if data were not provided, we excluded such studies. </p> <p>The review authors, after reading the full texts, independently assessed the eligibility of all trials identified using ad hoc eligibility, based on the inclusion criteria above. Disagreement among review authors was again discussed, and agreement was reached by consensus after involvement of a third review author. We contacted authors of multiple publications, which appeared to report on the same study, for clarification. A flow chart was included (<a href="#CD005573-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD005573-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD005573-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD005573-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LK and MG) carried out data extraction independently by using piloted forms. The data collected included information on the study design, participants, intervention and comparator, as well as outcome. Discrepancies in data extraction were discussed and if necessary, a third review author was consulted. LK and MG then entered data into the review file. </p> </section> <section id="CD005573-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors (LK and MG) independently carried out 'Risk of bias' assessment of the included studies. We used the Cochrane 'Risk of bias' tool in assessing the following domains (<a href="./references#CD005573-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p> <ul id="CD005573-list-0004"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessors</p> </li> <li> <p>Completeness of outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We considered subjective outcomes separately in our assessment of blinding and incompleteness of data. We judged studies to be at 'high', 'low' or 'unclear' risk of bias for each domain assessed. We judged the risk of bias across studies as follows. </p> <p> <ul id="CD005573-list-0005"> <li> <p>Low risk of bias (plausible bias unlikely to seriously alter the results) if all domains are at low risk of bias. </p> </li> <li> <p>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more domains are at unclear risk of bias. </p> </li> <li> <p>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more domains are at high risk of bias. </p> </li> </ul> </p> <p>Disagreements were resolved by consensus. We contacted study authors when insufficient information was provided to determine the risk of bias. Where we obtained information supporting our judgement on risk of bias through correspondence with study authors, we indicated this in the 'Risk of bias' table. </p> </section> <section id="CD005573-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed the treatment effect of dichotomous outcomes as risk ratios (RRs) and continuous outcomes as mean differences (MDs). In future updates, where studies measure the same outcome using different scales, we will express continuous outcomes as standardised mean differences (SMDs). For continuous data, we preferred final scores to change scores. We planned to express time to remission as median or hazard ratio (HR), but as data were not sufficiently reported this was unnecessary. </p> </section> <section id="CD005573-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. We dealt with studies involving multiple trial arms according to methods proposed in <a href="./references#CD005573-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a> (Section 16.5.4). We did not combine groups, but rather we used relevant groups as per the appropriate pair wise comparison. We considered unit of analysis issues arising from the measurement of outcomes at different time points. </p> </section> <section id="CD005573-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors for missing data. Where possible, we applied intention‐to‐treat analysis. We calculated missing standard deviations (SDs) from other reported data (such as P values, confidence intervals (CIs) and standard errors), where possible. However, we imputed missing data. If data was recorded from a graph, this was stated. In reporting adverse events, we assumed 'worst case' to avoid under reporting. For instance, we assumed that minor and serious adverse events were related to the intervention. </p> </section> <section id="CD005573-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>The decision to pool the results of individual studies depended on an assessment of clinical and methodological heterogeneity. If we considered studies sufficiently homogeneous for data pooling, we assessed statistical heterogeneity by visual inspection of the forest plots, and using the Chi<sup>2</sup> test with a significance level at P &lt; 0.1 and the I<sup>2</sup> statistic. We based our interpretation of the I<sup>2</sup> statistic results on those suggested by <a href="./references#CD005573-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a> (Section 9.5.2): </p> <p> <ul id="CD005573-list-0006"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%; may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD005573-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We avoided various reporting biases by undertaking an extensive literature search without restrictions on publication date or language. We used study protocols and trial registrations in assessing studies for selective reporting. If we had more than 10 studies, we would have generated a funnel plot. The magnitude of publication bias would have been initially determined by visual inspection of the asymmetry of the funnel plot. If this appeared asymmetric, we would have performed a linear regression of intervention effect estimate against its standard error, weighted by the inverse of the variance of the intervention effect estimate (<a href="./references#CD005573-bbs2-0037" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629.">Egger 1997</a>). P &lt; 0.1 would be an indication of a publication bias or small‐study effect. </p> </section> <section id="CD005573-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We analysed data using Review Manager 5 (<a href="./references#CD005573-bbs2-0052" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). For dichotomous outcomes, we derived RRs and 95% CIs for each study. For continuous outcomes, we derived MDs and 95% CIs. We combined the results of included studies for each outcome if appropriate. We used either fixed‐effect or random‐effects models, depending on the presence of statistical heterogeneity and the number or size of studies available. We considered not pooling data where there was considerable heterogeneity (I<sup>2</sup> ≥ 75%) which was not explained by clinical or methodological differences between the studies. However, we presented data which we were unable to pool as a narrative summary. </p> </section> <section id="CD005573-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We attempted to investigate unexplained heterogeneity. We checked the data, adjusted for heterogeneity by using a random‐effects model and then changed the measure of treatment effects from RR to odds ratios (OR), as proposed in section 9.5.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005573-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We undertook the following subgroup analyses. </p> <p> <ul id="CD005573-list-0007"> <li> <p>Paediatric versus adult population</p> </li> <li> <p>Single versus multiple strain probiotics</p> </li> </ul> </p> </section> <section id="CD005573-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to assess whether results of the review are robust to the decisions which were taken during the review process. We examined the effect on the review findings of: </p> <p> <ul id="CD005573-list-0008"> <li> <p>excluding studies at high risk of bias; and</p> </li> <li> <p>comparing the use of fixed‐effect versus random‐effects models.</p> </li> </ul> </p> </section> <section id="CD005573-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of evidence related to the primary outcomes listed in <a href="#CD005573-sec-0020">Types of outcome measures</a> (<a href="./references#CD005573-bbs2-0054" title="SchünemannH , HillS , GuyattG , et al. The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology &amp; Community Health2011;65:392-5.">Schünemann 2011</a>). The four levels of evidence certainty are 'high', 'moderate', 'low' or 'very low'. We downgraded the certainty of evidence due to study limitations (risk of bias), imprecision, inconsistency, indirectness or publication bias. </p> <p>Where there was sufficient evidence, we prepared 'Summary of findings' tables for our main comparisons; we presented the results for remission, disease improvement and adverse events. Two review authors (LK and MG) independently produced 'Summary of findings' tables using the GRADEpro GDT software (<a href="./references#CD005573-bbs2-0040" title="McMaster UniversityGRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.).Available from gradepro.org.">GRADEpro GDT 2015</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005573-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005573-sec-0039"></div> <section id="CD005573-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD005573-sec-0041"> <h4 class="title">Results of the search</h4> <p>The literature search conducted in December 2017 and updated in November 2019 provided 1302 studies once duplicates were removed, and one study identified through the previous review was added. Once we screened the titles and abstracts, and removed further duplicates, we found 35 studies that met the inclusion criteria. Full‐text copies were available for 33 of these studies. Further scrutiny identified 14 studies that met the inclusion criteria and we excluded 11 studies with reasons. We contacted authors of all 14 included studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>); two authors replied (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>). </p> <p>We identified one ongoing study and six studies are awaiting classification (<a href="./references#CD005573-sec-0128" title="">Characteristics of ongoing studies</a>; <a href="./references#CD005573-sec-0127" title="">Characteristics of studies awaiting classification</a>). </p> <p>The results of the search are presented in the PRISMA diagram (<a href="#CD005573-fig-0001">Figure 1</a>). Full details of the included and excluded studies are available in the <a href="./references#CD005573-sec-0125" title="">Characteristics of included studies</a> and <a href="./references#CD005573-sec-0126" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD005573-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD005573-sec-0043"> <h5 class="title">Study design and setting</h5> <p>We included 14 studies published between 1999 and 2019 (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). These studies were either single‐centred (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>), or multicentred (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>) parallel group RCTs. In two of these studies (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>), it was unclear whether they were single‐ or multicentred. The studies were conducted in China (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>), Japan (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>), Mexico (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>), Germany (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>), Italy (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>), UK (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), Iran (<a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>) and India (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>). For two studies, it is unclear where the studies took place and therefore we have assumed this to be the authors' affiliation and included <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a> (Russia) and <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a> (Italy). </p> </section> <section id="CD005573-sec-0044"> <h5 class="title">Participants</h5> <p>The average age of participants was between 12.5 years in <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a> and 47.7 years in <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>. Only three studies reported age ranges and two of these were looking at paediatric participants; 1.7 years in <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a> to 18 years in <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>. The studies randomised 20 participants in <a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a> to 147 in <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>, and had a mixture of male and females. One study did not mention the number of participants it had nor the demographics of the participants (<a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). All participants may or may not have been receiving medication concurrently in the studies. Five studies described the extent of disease in participants, which included proctitis, left colon involved, proctosigmoiditis and total/subcolitis (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). Two studies reported on smoking amongst participants (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). Five studies used either clinical, endoscopic, histological and/or radiological criteria to confirm that its participants had active colitis on recruitment (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>). Only one study provided information that its participants had disease duration of more than five years (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>). </p> </section> <section id="CD005573-sec-0045"> <h5 class="title">Interventions</h5> <p>All of the included studies had two trial arms, apart from <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a> and <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>, with four arms. <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> had three probiotic arms with increasing strengths and one control group. <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a> had one trial arm with probiotics, one with conventional treatment, one with a combination, and one control group that received nothing. </p> <p>The studies investigated the following comparisons.</p> <p> <ul id="CD005573-list-0009"> <li> <p>Probiotic versus placebo (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). </p> </li> <li> <p>Probiotic versus 5‐aminosalicylic acid (5‐ASA) (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </li> <li> <p>Probiotic and 5‐ASA versus 5‐ASA (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). </p> </li> <li> <p>Probiotic and 5‐ASA versus 5‐ASA versus probiotic versus nothing (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>). </p> </li> </ul> </p> <p>Single strains of bacteria were tested in seven studies (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). The other seven tested multiple strains. The single strains of bacteria that were tested include <i>Echerichia coli (E coli)</i> strain Nissle 1917 (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>), <i>Lactobacillus reuteri</i> (<i>L reuteri</i>) ATCC 55730 (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>), <i>E Coli</i> (serotype 06:K5:H1) (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), <i>Bifidobacterium</i> 536 (<a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>), <i>L casei</i> strain ATCC PTA‐3945 (<a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>), <i>Enteroccus faecium</i> (<i>E faecium</i>) L‐3 (<a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). </p> <p>We studied the following combinations.</p> <p> <ul id="CD005573-list-0010"> <li> <p>Six strains of <i>Lactobacillus plantarum (L plantarum), Lactobacillus acidophilus (L acidophilus), Lactobacillus rhamnosus (L rhamnosus), Lactobacillus bifidus (L bifidus), L casei</i> and <i>Bifidobacterium infantis (B infantis)</i> (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). </p> </li> <li> <p><i>Bifidobacterium breve (B breve), Bifidobacterium bifidum (B bifidum)</i> and <i>Lactobacillus acidophilus (L acidophilus)</i> YIT 0168 (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>). </p> </li> <li> <p>Four strains of <i>Lactobacillus (L paracasei, L plantarum, L acidophilus, L delbrueckii subsp bulgaricus),</i> three strains of <i>Bifidobacterium (B longum, B breve</i> and <i>B infantis),</i> and one strain of <i>Streptococcus salivaria (S salivaria) subsp thermophiles</i> (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). </p> </li> <li> <p>Four and three strains of <i>Bifidobacterium</i> in <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a> and <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>, respectively. </p> </li> <li> <p>Two strains of probiotic and one strain of prebiotic (<i>Bifidobacterium (B bifidum), lactobacillus bulgaricus (L bulgaricus), streptococcus thermophilus (S thermophilus)</i>) (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>). </p> </li> </ul> </p> <p>Interventions were administered daily for two weeks in <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> to 52 weeks in <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>. Concomitant treatments were used in nine studies (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>), and it was unclear in the other four studies if concomitant treatment was allowed. Concomitant treatment ranged from loperamide drops (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>), gentamicin for one week (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), oral 5‐ASA (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>), oral 5‐ASA, azathioprine and 6‐mercaptopurine (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>), and/or steroid therapy (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>). </p> <p>Two studies administered their probiotic therapy rectally (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>), whilst the rest did so orally. </p> </section> <section id="CD005573-sec-0046"> <h5 class="title">Outcomes</h5> <p> <ul id="CD005573-list-0011"> <li> <p>Remission was reported in 12 of the 14 studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). Of the 12 studies reporting on remission, <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a> did not provide a definition of remission, <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a> assessed remission based on the Sunderland disease activity index, and the remaining studies reported on clinical remission. </p> </li> <li> <p>Withdrawals due to adverse events were reported in one study (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>). </p> </li> <li> <p>Serious adverse events were reported in eight studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). </p> </li> <li> <p>Minor adverse events were reported in nine studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </li> <li> <p>Time to remission was reported in three studies (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). </p> </li> <li> <p>Disease improvement was reported as improvement in clinical (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>), endoscopic (<a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>), and histological scores (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). </p> </li> <li> <p>Histology scores were reported in five studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). </p> </li> <li> <p>Biochemical scores were reported in two studies (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </li> <li> <p>Steroid withdrawal, need for additional therapy, progression to therapy, clinical scores and quality of life scores were not reported in any of the studies. </p> </li> </ul> </p> <p>Data on the above outcomes were collected and presented in <a href="#CD005573-tbl-0004">Table 1</a>. </p> <div class="table" id="CD005573-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table showing outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number induced</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Minor adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events requiring withdrawal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10 versus 3/10</p> <p>40% versus 33%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absence of rectal bleeding, a rectal mucosa without erythaema, granularity, or friability and normal or near‐normal sigmoidoscopic findings </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 1/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/70 versus 2/20</p> <p>49% versus 45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical DAI ≤ 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported on graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/10 versus 10/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/70 versus 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/70 versus 3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/14 versus 4/15</p> <p>93% versus 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occurrence or worsening of symptoms, accompanied by an increase in LCAI &gt; 3, sufficient to require treatment with corticosteroids, azathioprine/immunosuppressive agents or surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 versus 0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 versus 0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 versus 0/20</p> <p>25% versus 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final DAI score &lt; 2 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/57 versus 44/59</p> <p>66% versus 77%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General well‐being with the passage of no more than three formed stools per day, a rectal mucosa without erythaema, granularity or friability as well as histological confirmation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Mean)</p> <p>42 days versus 44 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/57 versus 7/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 versus 2/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 versus 2/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/28 versus 12/28</p> <p>54% versus 43%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI scores of 0‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28 versus 0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28 versus 0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28 versus 0/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/17 versus 13/17</p> <p>82% versus 76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient not having more than 3 well‐formed stools per day and without visible blood in the stools and any clinical symptoms of ulcerative colitis and had a clinical activity index &lt; 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Mean)</p> <p>25 days versus 32 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/17 versus 12/17:</p> <p>unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17 versus 0/17:</p> <p>unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/71 versus 23/73</p> <p>44% versus 32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI score &lt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/71 versus 9/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/71 versus 0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/77 versus 11/70</p> <p>43% versus 16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI scores not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/77 versus 0/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/77 versus 0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/42 versus 32/42</p> <p>90% versus 76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on the Suntherland disease activity index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/17 versus 0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission, considered in patient without bloody diarrhoea, without tachycardia, without fever, without anaemia and normal ESR and/or CRP (provided by author via email on 17/12/2019) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20, 0/20, 0/20</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Note: steroid withdrawal, biochemical markers of inflammation, histology scores, need for additional therapy, progression to surgery, clinical scores, and quality of life scores have not been reported in any of the studies. </p> <p>DAI: disease activity index; CRP: c‐reactive protein; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; UCDAI: ulcerative colitis activity index; </p> </div> </div> </section> <section id="CD005573-sec-0047"> <h5 class="title">Funding and declaration of interest</h5> <p>Funding was not stated for seven studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). Two studies stated that they received no external sources of funding (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>). Two studies were funded by pharmaceutical industries (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>), one study by an independent foundation (<a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>), one study by a charity (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), and one study was funded by several government bodies (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>). </p> <p>Seven studies declared no conflicts of interest (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). The other seven studies did not report on conflicts of interest (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </section> </section> <section id="CD005573-sec-0048"> <h4 class="title">Excluded studies</h4> <p>Eleven studies failed to meet the inclusion criteria for the following reasons.</p> <p> <ul id="CD005573-list-0012"> <li> <p>Full text article could not be found (<a href="./references#CD005573-bbs2-0016" title="BatagaSM , TorokI , MacarieM , NegovanA , BotianuA . Rifaximine and probiotics in the treatment of mild relapse of left sided ulcerative colitis. European Journal of Clinical Investigation2015;45:39-40. ">Bataga 2015</a>). </p> </li> <li> <p>Induction and maintenance data presented together (<a href="./references#CD005573-bbs2-0018" title="FujimoriS , GudisK , MitsuiK , SeoT , YonezawaM , TanakaS , et al. A randomized controlled trial on the efficacy of symbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition2009;25(5):520-5. ">Fujimori 2009</a>). </p> </li> <li> <p>Crohn's disease and ulcerative colitis data presented together (<a href="./references#CD005573-bbs2-0015" title="BalliniA , SantacroceL , CantoreS , BottalicoL , DipalmaG , TopiS , et al. Probiotics efficacy on oxidative stress values in inflammatory bowel disease: a randomized double-blinded placebo-controlled pilot study. Endocrine, Metabolic &amp; Immune Disorders - Drug Targets2019;19(3):373-81. ">Ballini 2019</a>; <a href="./references#CD005573-bbs2-0019" title="IRCT20120415009475N5. Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD) [Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD)]. www.irct.ir/trial/32179 Registration date 10 October 2018. ">IRCT20120415009475N5</a>). </p> </li> <li> <p>Commentary piece (<a href="./references#CD005573-bbs2-0025" title="TurcotteJF , HuynhHQ . Treatment with the probiotic VSL#3 as an adjunctive therapy in relapsing mild-to-moderate ulcerative colitis significantly reduces ulcerative colitis disease activity. Evidence-Based Medicine2011;16(4):108-9. ">Turcotte 2011</a>). </p> </li> <li> <p>Cross‐over study that presented induction and maintenance results together (<a href="./references#CD005573-bbs2-0021" title="KragA , MunkholmP , IsraelsenH , RybergB , AndersenKK , BendtsenF . Profermin is efficacious in patients with active ulcerative colitis - a randomized controlled trial. Inflammatory Bowel Disease2013;19(12):2584-92. ">Krag 2013</a>). </p> </li> <li> <p>Participants had inactive disease (<a href="./references#CD005573-bbs2-0017" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>). </p> </li> <li> <p>Outcomes did not include inducing remission (<a href="./references#CD005573-bbs2-0020" title="IshikawaH , AkedoI , UmesakiY , TanakaR , Imaoka, OtaniT . Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition2003;22(1):56-63. ">Ishikawa 2003</a>). </p> </li> <li> <p>Not randomised (<a href="./references#CD005573-bbs2-0024" title="Santana PorbenS . Influence of a combination of lactobacilli and bifidobacteria upon disease activity, stool pattern and nutritional status of ulcerative colitis patients. Spanish society of parenteral and enteral nutrition2010;25(6):971-83. ">Santana 2010</a>). </p> </li> <li> <p>Insufficient information on study details and no response from authors when contacted (<a href="./references#CD005573-bbs2-0023" title="NCT00895336. Lactobacillus GG in pediatric ulcerative colitis. clinicaltrials.gov/show/NCT00895336 (first received 8 May 2009). ">NCT00895336</a>; <a href="./references#CD005573-bbs2-0022" title="NCT00374725. Treatment of ulcerative colitis with a combination of lactobacillus rhamnosus and lactobacillus acidophilus. www.clinicaltrials.gov/ct2/show/NCT00374725 (first received 11 September 2006). ">NCT00374725</a>). </p> </li> </ul> </p> </section> </section> <section id="CD005573-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The studies were either at high or unclear risk of bias. The risk of bias for the studies is summarised in <a href="#CD005573-fig-0002">Figure 2</a> and <a href="#CD005573-fig-0003">Figure 3</a>. Further details are available in the <a href="./references#CD005573-sec-0125" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD005573-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005573-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005573-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005573-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005573-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD005573-sec-0051"> <h5 class="title">Sequence generation</h5> <p>All of the included studies described their studies as random with regards to allocation of participants to intervention or control groups. The method of randomisation was adequately described in 10 studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). The remaining studies did not mention their methods of randomisation; we contacted the authors for clarification, but received no response (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). There was also insufficient information on how the randomisation list was generated in <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>. </p> </section> <section id="CD005573-sec-0052"> <h5 class="title">Allocation sequence concealment</h5> <p>We judged this as low risk of bias for three studies (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>). These studies described the use of central allocation (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), opaque, sealed and numbered envelopes (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>), and identical interventions with specific participant numbers being used to mark delivery containers (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>). </p> <p>We judged risk of bias as unclear for 11 studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </section> </section> <section id="CD005573-sec-0053"> <h4 class="title">Blinding</h4> <p>Eight studies were described as double‐blinded (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). However, we only judged two of the 11 studies as low risk for both performance and detection bias (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>). We judged six studies as low risk for performance bias (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>), five as unclear, due to insufficient detail (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>), and three studies as high risk due to the intake of medication for the probiotic and control group being different (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). </p> <p>For detection bias, we judged 11 studies as unclear (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019;</a><a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017;</a><a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). </p> </section> <section id="CD005573-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Six studies were at low risk of bias for reporting data for all participants (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019;</a><a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). Four studies were unclear (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014;</a><a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>). Four studies were at high risk of bias due to high attrition rates (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>), and non‐reporting of outcome data for all participants in one study group (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>). </p> </section> <section id="CD005573-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Trial registration was available for one study (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>), which failed to report on all prespecified outcomes. We judged four additional studies as high risk of bias for mentioning non‐significant results without reporting outcome data (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>), and measuring outcomes without reporting them (<a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). </p> <p>We judged seven studies as low risk of bias. Six studies did not have a trial registration, but all expected outcomes were reported (<a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). Two studies were unclear due to insufficient information (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). </p> </section> <section id="CD005573-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 10 studies as low of bias (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). We judged two studies as high risk of bias due to participants being classified according to disease severity and being given specific concomitant treatments, which put randomisation into question (<a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>), and imbalance in important baseline characteristics (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). We judged two studies as unclear, as no clear statement was made that the participants were equally matched in <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>, and <a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a> failed to provide sufficient information for a judgement to be made. </p> </section> </section> <section id="CD005573-sec-0057"> <h3 class="title" id="CD005573-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD005573-tbl-0001"><b>Summary of findings 1</b> Probiotics compared to placebo for induction of remission in ulcerative colitis</a>; <a href="./full#CD005573-tbl-0002"><b>Summary of findings 2</b> Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</a>; <a href="./full#CD005573-tbl-0003"><b>Summary of findings 3</b> Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</a> </p> <section id="CD005573-sec-0058"> <h4 class="title">Probiotics versus placebo</h4> <p>Ten studies compared probiotics with placebo (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>; <a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). See <a href="./full#CD005573-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD005573-sec-0059"> <h5 class="title">Primary outcomes</h5> <section id="CD005573-sec-0060"> <h6 class="title">Clinical remission</h6> <p>There is low‐certainty evidence that probiotics may improve induction of clinical remission, when compared with placebo (risk ratio (RR) 1.73, 95% confidence interval (CI) 1.19 to 2.54; 9 studies, 594 participants; I<sup>2</sup> = 55%; random‐effects model; <a href="./references#CD005573-fig-0006" title="">Analysis 1.1</a>, number needed to treat for an additional beneficial outcome of 5). We downgraded the evidence for high risk of bias in the majority of studies and imprecision due to sparse data. We did not downgrade for inconsistency as the effect estimates appeared to be fairly consistent across studies and we judged heterogeneity to be as a result of differences in probiotic preparations. </p> <section id="CD005573-sec-0061"> <p><b>Sensitivity analysis</b></p> <p>We analysed the data using a fixed‐effect model and obtained similar, but more precise results (RR 1.78, 95% CI 1.41 to 2.25; 9 studies, 560 participants; I<sup>2</sup> = 55%; low‐certainty evidence). Further exclusion of the studies at high risk of bias from the main analysis found that it is uncertain whether probiotics lead to a difference in clinical remission (RR 2.04, 95% CI 0.83 to 4.96; 2 studies, 71 participants; I<sup>2</sup> = 72%; very low‐certainty evidence). </p> </section> <section id="CD005573-sec-0062"> <p><b>Subgroup analysis</b></p> <p>We carried out the subgroup analysis to investigate whether age is an effect modifier. The analysis found probiotics to be beneficial in both adults (RR 1.49, 95% CI 1.07 to 2.08; 525 participants, 7 studies; I<sup>2</sup> = 43%; very low‐certainty evidence, number needed to treat for an additional beneficial outcome of 7) and children (RR 3.83, 95% 1.69 to 8.66; 2 studies, 69 participants; I<sup>2</sup> = 0%; low‐certainty evidence, number needed to treat for an additional beneficial outcome of 3), with a slightly greater effect in the paediatric population (test for subgroup differences: Chi² = 4.42, P = 0.04, I² = 77.4%) (<a href="./references#CD005573-fig-0007" title="">Analysis 1.2</a>, <a href="#CD005573-fig-0004">Figure 4</a>). These results are similar to those obtained in the main analysis, but should be interpreted cautiously, given the small number of studies analysed. </p> <div class="figure" id="CD005573-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.2 Clinical remission: subgroup analysis by age." data-id="CD005573-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.2 Clinical remission: subgroup analysis by age. </p> </div> </div> </div> <p>We also assessed whether clinical remission was affected by the number of strains in probiotics. There was neither a qualitative nor quantitative difference between probiotics with multiple strains (RR 2.02, 95% CI 1.31 to 3.12; 5 studies, 374 participants; I<sup>2</sup> = 32%) and those with single strains (RR 1.44, 95% CI 0.79 to 2.63; 4 studies, 220 participants; I<sup>2</sup> = 57%) (<a href="./references#CD005573-fig-0008" title="">Analysis 1.3</a>). Subgroup analyses are rarely informative when there are sparse data, therefore, these results should be interpreted with caution. </p> </section> </section> <section id="CD005573-sec-0063"> <h6 class="title">Histological remission</h6> <p>It is unclear whether probiotics lead to a difference in histological remission when compared with placebo due to very low‐certainty evidence (RR 2.50, 95% CI 0.56 to 11.16; 1 study, 34 participants). We downgraded the evidence once due to high risk of bias and twice for very serious imprecision (<a href="./references#CD005573-fig-0009" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD005573-sec-0064"> <h5 class="title">Secondary outcomes</h5> <section id="CD005573-sec-0065"> <h6 class="title">Disease improvement</h6> <p>There was improved clinical disease severity when probiotics were compared with placebo (RR 2.29, 95% CI 1.13 to 4.63; 2 studies, 54 participants; low‐certainty evidence). We downgraded the evidence once for risk of bias and once due to serious imprecision. There is moderate‐certainty evidence showing that probiotics probably reduce disease severity assessed by endoscopic scores when compared with placebo (RR 1.45, 95% CI 1.03 to 2.05; 1 study, 144 participants). We downgraded the evidence once due to imprecision due to the small number of participants. It is uncertain whether probiotics result in a difference in histological improvement when compared with placebo because the evidence is of very low certainty (RR 2.00, 95% CI 1.09 to 3.68; 1 study, 34 participants) (<a href="./references#CD005573-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD005573-sec-0066"> <h6 class="title">Steroid withdrawal</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0067"> <h6 class="title">Clinical activity scores</h6> <p>Clinical activity scores were reported in one study (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>). In the probiotics and placebo groups, the mean was 10.9 versus 11.1. However, measures of variance were not reported. </p> </section> <section id="CD005573-sec-0068"> <h6 class="title">Histology scores</h6> <p>Histology scores were reported in three studies (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>). MDs ranged between ‐3.38 and ‐0.95 in the three studies (79 participants). We did not pool data due to considerable heterogeneity (I<sup>2</sup> = 90%; <a href="./references#CD005573-fig-0012" title="">Analysis 1.7</a>). However, two studies with sufficient data consistently showed lower histology scores in the probiotics group (low‐certainty evidence). </p> </section> <section id="CD005573-sec-0069"> <h6 class="title">Biochemical markers of inflammation</h6> <p><a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a> measured C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR), however, no data were reported. Other markers of inflammation were reported in <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>. We manually extracted the data on tumour necrosis factor (TNF)TNF ‐ α, interleukin 10 (IL‐10), interleukin 1 beta (IL‐1β) and interleukin 8 (IL‐8) from graphs, as shown in <a href="./references#CD005573-fig-0013" title="">Analysis 1.8</a>. </p> </section> <section id="CD005573-sec-0070"> <h6 class="title">Need for additional therapy</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0071"> <h6 class="title">Progression to surgery</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0072"> <h6 class="title">Symptomatic severity (stool frequency, abdominal pain)</h6> <p>This outcome was reported in five studies in different ways (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>, <a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>; <a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>; <a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>). </p> <p> <ul id="CD005573-list-0013"> <li> <p><a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> measured defecation frequency, occurrence of rectal bleeding, general disease activity, self‐assessments by participants and investigators, as well as global assessment of health. However, data were not shown. </p> </li> <li> <p><a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a> reported on physicians global assessment of disease and the proportion with moderate (42% versus 33%) and severe (58% versus 67%) activity of disease were reported. The mean clinical activity scores were 10.9 (14 participants) versus 11.11 (15 participants) in the probiotics and placebo groups, respectively. Measures of variance were not reported, therefore, we could not analyse this data (<a href="./references#CD005573-fig-0011" title="">Analysis 1.6</a>). </p> </li> <li> <p><a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a> reported a physician global assessment score of 0.68 (probiotics) versus 1.1 (placebo); stool frequency score 1.04 (probiotics) versus 1.66 (placebo); and rectal bleeding score 0.48 (probiotics) versus 1.01 (placebo). </p> </li> <li> <p><a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a> measured rectal bleeding (figures reported in text and graph were inconsistent, therefore, not presented); stool frequency (data not shown); and physicians global score (data not shown). </p> </li> <li> <p><a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a> reported on the proportion of participants with improvement in stool frequency (48% for probiotics versus 38% for placebo); improvement of physician rating of disease activity (43% for probiotics versus 25% for placebo); and reduction of rectal bleeding (55% for probiotics versus 31% for placebo). </p> </li> </ul> </p> </section> <section id="CD005573-sec-0073"> <h6 class="title">Quality of life scores</h6> <p><a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> measured quality of life (using a visual analogue scale (VAS)), however, data were not shown. </p> </section> <section id="CD005573-sec-0074"> <h6 class="title">Time to remission/improvement</h6> <p>Time to remission was reported in two studies (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>; <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>). <a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> stated that "time to remission was shorter in the 40 mL and 20 mL <i>Escherichia coli</i> Nissle (EcN) groups than in the 10 mL EcN and placebo groups. <a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a> reported median time to remission of 23 days and 25 days with probiotics and placebo, respectively. Data were not sufficiently reported in either study, to allow further analysis. </p> </section> <section id="CD005573-sec-0075"> <h6 class="title">Minor adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in the occurrence of minor adverse events when compared with placebo (RR 1.04, 95% CI 0.42 to 2.59; I<sup>2</sup> = 69%; 7 studies, 520 participants; random‐effects model; <a href="./references#CD005573-fig-0014" title="">Analysis 1.9</a>). We downgraded the evidence for high risk of bias, inconsistency (I<sup>2</sup> = 69%), and imprecision, as the CI included a risk of benefit and harm. </p> </section> <section id="CD005573-sec-0076"> <h6 class="title">Serious adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in the occurrence of serious adverse events when compared with placebo (RR 0.09, CI 0.01 to 1.66; 7 studies, 526 participants; very low‐certainty evidence; <a href="./references#CD005573-fig-0015" title="">Analysis 1.10</a>, <a href="#CD005573-fig-0005">Figure 5</a>). We downgraded the evidence for high risk of bias and imprecision, as the CI included a risk of benefit and harm. </p> <div class="figure" id="CD005573-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.10 Serious adverse events." data-id="CD005573-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.10 Serious adverse events. </p> </div> </div> </div> </section> <section id="CD005573-sec-0077"> <h6 class="title">Withdrawal due to adverse events</h6> <p>There is low‐certainty evidence showing that probiotics make little or no difference in the number of people needing to withdraw due to adverse events when compared with placebo (RR 0.85, CI 0.42 to 1.72; 4 studies, 401 participants; low‐certainty evidence; <a href="./references#CD005573-fig-0016" title="">Analysis 1.11</a>). We downgraded the evidence for imprecision due to wide CIs which includes a risk of benefit and harm. </p> </section> </section> </section> <section id="CD005573-sec-0078"> <h4 class="title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</h4> <p>Two studies compared probiotics with 5‐ASA (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>). See <a href="./full#CD005573-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD005573-sec-0079"> <h5 class="title">Primary outcome</h5> <section id="CD005573-sec-0080"> <h6 class="title">Clinical remission</h6> <p>It is uncertain whether probiotics lead to a difference in the number of people who attain remission when compared with 5‐ASA (RR 0.92, 95% CI 0.73 to 1.16; 1 study, 116 participants; low‐certainty evidence; <a href="./references#CD005573-fig-0017" title="">Analysis 2.1</a>). We downgraded the evidence for high risk of bias and imprecision due to this being a single study with a small number of participants. </p> </section> </section> <section id="CD005573-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD005573-sec-0082"> <h6 class="title">Disease improvement</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0083"> <h6 class="title">Steroid withdrawal</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0084"> <h6 class="title">Clinical activity scores</h6> <p>There is low‐certainty evidence that probiotics may slightly reduce clinical activity scores compared to 5‐ASA (mean difference (MD) ‐2.07, 95% CI ‐3.22 to ‐0.92; 1 study, 76 participants; <a href="./references#CD005573-fig-0018" title="">Analysis 2.2</a>). Our confidence in the result is limited as the evidence is from a small study which reported no information to allow us to judge risk of bias in any of the domains. </p> </section> <section id="CD005573-sec-0085"> <h6 class="title">Histology scores</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0086"> <h6 class="title">Biochemical markers of inflammation</h6> <p>One study (76 participants) reported on the effect of probiotics compared to 5‐ASA on serum IL‐4 (MD 2.53, 95% CI 0.47 to 4.59), serum IL‐8 (MD ‐66.10, 95% CI ‐71.63 to ‐60.57) and high‐sensitivity C‐reactive protein (hs‐CRP) (MD ‐3.03, 95% CI ‐3.45 to ‐2.61). Our confidence in the result is limited as the evidence is from a small study which reported no information to allow us to judge risk of bias in any of the domains (<a href="./references#CD005573-fig-0019" title="">Analysis 2.3</a>). </p> </section> <section id="CD005573-sec-0087"> <h6 class="title">Need for additional therapy</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0088"> <h6 class="title">Progression to surgery</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0089"> <h6 class="title">Symptomatic severity (stool frequency, abdominal pain)</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0090"> <h6 class="title">Quality of life scores</h6> <p>This outcome was not reported.</p> </section> <section id="CD005573-sec-0091"> <h6 class="title">Time to remission/improvement</h6> <p>There is low‐certainty evidence that in any given number of people receiving therapy for the induction of remission, 50% may achieve remission in less time with probiotics than placebo (37 days versus 42 days; 116 participants; reported P = 0.0092). We downgraded for high risk of bias and imprecision due to small sample size from a single study. </p> </section> <section id="CD005573-sec-0092"> <h6 class="title">Minor adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in minor adverse events because the certainty of the evidence is very low (RR 1.23, 95% CI 0.56 to 2.70; 2 studies, 192 participants; very low‐certainty evidence; <a href="./references#CD005573-fig-0020" title="">Analysis 2.4</a>). We downgraded the evidence due to high risk of bias and imprecision due to small sample size and sparse data. </p> </section> <section id="CD005573-sec-0093"> <h6 class="title">Serious adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in serious adverse events because the certainty of the evidence is very low (RR 0.21, 95% CI 0.01 to 4.22; 1 study, 116 participants; very low‐certainty evidence; <a href="./references#CD005573-fig-0021" title="">Analysis 2.5</a>). We downgraded the evidence due to high risk of bias and imprecision due to small sample size and sparse data from a single study. </p> </section> <section id="CD005573-sec-0094"> <h6 class="title">Withdrawal due to adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in withdrawals due to adverse events because the certainty of the evidence is very low (RR 0.21, 95% CI 0.01 to 4.22; 1 study, 116 participants; very low‐certainty evidence; <a href="./references#CD005573-fig-0022" title="">Analysis 2.6</a>). We downgraded the evidence due to high risk of bias and imprecision due to small sample size and sparse data from a single study. </p> </section> </section> </section> <section id="CD005573-sec-0095"> <h4 class="title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine)</h4> <p>Three studies compared probiotics plus 5‐ASA to 5‐ASA (<a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a>; <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>). See <a href="./full#CD005573-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD005573-sec-0096"> <h5 class="title">Primary outcome</h5> <section id="CD005573-sec-0097"> <h6 class="title">Remission (based on Sunderland disease activity scores)</h6> <p>There is low‐certainty evidence that probiotics, when coupled with 5‐ASA, may slightly increase the number of people who attain remission when compared with 5‐ASA alone (RR 1.22, CI 1.01 to 1.47; 1 study, 84 participants; low‐certainty evidence; <a href="./references#CD005573-fig-0023" title="">Analysis 3.1</a>). We downgraded the evidence for unclear risk of bias in most of the domains and imprecision due to small sample size of a single study. </p> </section> </section> <section id="CD005573-sec-0098"> <h5 class="title">Secondary outcomes</h5> <section id="CD005573-sec-0099"> <h6 class="title">Symptomatic severity (stool frequency, abdominal pain)</h6> <p>Clinical activity scores were reported in <a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a>. However, the number of participants randomised to each group was not stated, therefore we were unable to analyse the data. Mean scores were 4.5 (SD 1.5) versus 6.7 (SD 1.3) in 47 participants. </p> <p>None of the other secondary outcomes were reported.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005573-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005573-sec-0100"></div> <section id="CD005573-sec-0101"> <h3 class="title" id="CD005573-sec-0101">Summary of main results</h3> <p>This review included 14 parallel group randomised controlled trials (RCTs) assessing the effectiveness of probiotics in inducing remission in ulcerative colitis. All the studies except <a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a> provided sufficient data for inclusion in a meta‐analysis. The comparisons assessed by the studies were probiotics versus placebo, probiotics versus 5‐aminosalicylic acid (5‐ASA) and probiotics plus 5‐ASA versus 5‐ASA alone. See <a href="./full#CD005573-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD005573-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD005573-tbl-0003">summary of findings Table 3</a>. </p> <p>We analysed and summarised data from 865 participants.</p> <p> <ul id="CD005573-list-0014"> <li> <p>Probiotics may improve induction of clinical remission when compared with placebo (low‐certainty evidence). </p> </li> <li> <p>There may be little or no difference in the induction of remission with probiotics when compared with 5‐ASA (low‐certainty evidence). </p> </li> <li> <p>There is limited evidence to show that probiotics plus 5‐ASA may slightly improve the induction of remission (based on the Sunderland disease activity index) when compared with 5‐ASA alone (low‐certainty evidence). </p> </li> <li> <p>Probiotics probably reduce disease severity, based on endoscopic scores, when compared with placebo (moderate‐certainty evidence). </p> </li> <li> <p>Probiotics may improve clinical disease severity when compared with placebo (low‐certainty evidence). </p> </li> <li> <p>The most common minor adverse events were abdominal bloating and discomfort (very low‐certainty evidence). </p> </li> <li> <p>All seven studies comparing probiotics with placebo, which recorded serious adverse events, reported no events occurring with probiotics (very low‐certainty evidence). </p> </li> <li> <p>Probiotics may make little or no difference in the number of people withdrawing from treatment due to adverse events compared to placebo (low‐certainty evidence). </p> </li> <li> <p>There were insufficient data on biochemical markers of inflammation, time to remission, symptomatic severity, histology scores and clinical activity scores. </p> </li> <li> <p>None of the studies reported on steroid withdrawal, need for additional therapy, or quality of life scores. </p> </li> </ul> </p> </section> <section id="CD005573-sec-0102"> <h3 class="title" id="CD005573-sec-0102">Overall completeness and applicability of evidence</h3> <p>The range of studies analysed in this review led to heterogeneity in all aspects. This produces limitations when trying to apply a guide to decision making. When shared decision making is made by clinicians and practitioners, they need not only facts, but pragmatic and useful ways of applying those facts to their individual patients. The clinical heterogeneity in almost all areas (e.g. methods of identifying disease activity as baseline, methods of defining remission, improvement, adverse events, the huge range of individual patient demographics, the routes of administration, and specific strains of probiotics) really limits the way in which these findings can be confidently applied to individual patients. </p> <p>Updating this review after almost 10 years has highlighted the growing body of evidence, but it is disappointing that these barriers to the utility of the evidence base exists. Indeed, this raises the question, as to why strategically over the years, studies have not looked to build sequentially on one another. When synthesising studies in this review, the field appears to comprise of disparate works produced in isolation of the wider clinical research field. </p> <p>There is insufficient information to fully describe the relevance of the evidence due to poor reporting across the studies. None of the studies were restrictive in terms of gender or age, there were some restrictions on the severity of ulcerative colitis, as no study chose to include participants with severe disease. Apart from two studies (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>), all studies recruited adults. A formal subgroup analysis looking at age as an effect modifier, found no qualitative difference in remission between the adult and paediatric population. However, there is a quantitative difference between adults and children. When we further analysed the data by number of strains, there was neither a qualitative nor quantitative difference. Given the insufficient data these findings should be interpreted with caution. We intend to explore these subgroups in future updates when more trials become available. </p> <p>Follow‐up ranged from two weeks to 52 weeks. Eight out of the 12 studies used concomitant treatment, and for a further two studies it was not clear whether concomitant treatment was allowed. This causes uncertainty in terms of attributing treatment effects or adverse events to the concomitant treatment or the study intervention itself. <a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a> also reported on adverse outcomes, however it presented its data from induction and maintenance together, which made it unclear to analyse, it also used gentamicin for one week prior to the start of the study, so it is difficult to assess whether the adverse events were caused by the intervention or prior treatment. </p> <p>Six out of the 12 studies had probiotics that were directly supplied by the pharmaceutical manufacturer. For the other six studies, it was possible to search for an online retailer who sold the probiotic, however the studies themselves did not identify the source of their intervention. The probiotics used were both yogurt drinks and food supplements. </p> <p>Time to remission was reported in two studies, however one study reported this as mean number of days, and the second study provided a graph, which made it unclear to derive statistical data from. </p> </section> <section id="CD005573-sec-0103"> <h3 class="title" id="CD005573-sec-0103">Certainty of the evidence</h3> <p>The certainty of the evidence ranged from moderate to very low. However, the moderate graded evidence only included one study. The main reasons for low grades of evidence were imprecision, due to small numbers, or high/unclear risk of bias. The issue with risk of bias is particularly pervasive in the field, and is a largely avoidable barrier impacting the certainty of the evidence in this review. Most of the studies failed to describe the blinding of outcome assessors adequately and also failed to adequally report on allocation concealment. Two studies mentioned that histopathologists were blinded, but failed to explicitly mention if other outcome assessors were also blinded. Two studies had to be translated into English, and one study was an abstract, which was unclear for most domains in risk of bias. Whilst it is possible that there was genuine bias within the studies, most of these sources would easily be managed through following international guidance on trial design. Similarly, poor reporting should also be easily addressed through peer review, ensuring these are addressed prior to publication. As it stands, we downgraded every outcome comparison due to the risk of bias. </p> <p>The study samples ranged from 20 to 147 participants; these small numbers resulted in wide confidence intervals (CIs). Indeed, whilst some studies produced power calculations, the assumptions they used are very much out of keeping with the size of treatment effects that are seen across Cochrane Inflammatory Bowel Disease portfolios of reviews, and as such the question as to whether these studies were underpowered remains. This is once again a pervasive problem across the field. </p> <p>Due to moderate and substantial heterogeneity, we downgraded for inconsistency. These inconsistencies may be explained by significant differences in clinical characteristics across the studies, however, there were insufficient data to investigate further. </p> <p>There was no indirectness, as the included studies all addressed the objectives of the review, and were within the scope. The number of studies included in the meta‐analysis was insufficient to assess for publication bias (less than 10). </p> </section> <section id="CD005573-sec-0104"> <h3 class="title" id="CD005573-sec-0104">Potential biases in the review process</h3> <p>Some studies reported outcomes as proportions; in order to include the data in the analysis, we calculated the number of events. We were able to minimise errors by having two independent review authors extract the data. The review authors contacted study authors for additional information and clarifications, however some authors failed to reply. We aim to include any data which become available in future updates. </p> <p>We had less than the recommended number of studies required to carry out a subgroup analysis, but still analysed the results by age to assess whether it was an effect modifier. We are aware that this can lead to type I error and have advised that the results be interpreted cautiously. </p> <p>One study is only available as an abstract and a second study did not provide sufficient data. We did not explore the impact of these studies in a sensitivity analysis. </p> <p>We are aware of the possible impact of industry funding on the validity of trial results. Funding form manufacturing companies or any conflicts of interests that were declared were noted in the relevant studies, but in many studies these details were simply omitted. We did not take these into account in carrying out the 'Risk of bias' assessment of the studies or GRADE assessment of the evidence. </p> </section> <section id="CD005573-sec-0105"> <h3 class="title" id="CD005573-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>There is currently no other known evidence‐based guidance or systemic review around the use of probiotics for the induction of remission in ulcerative colitis, except the previous version of the review (<a href="./references#CD005573-bbs2-0061" title="MallonPT , McKayD , KirkSJ , GardinerK . Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005573]">Mallon 2007</a>). The European Crohn's and Colitis Organisation (ECCO) and European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPHGAN) guideline recommends the use of probiotics as add‐on therapy for adults and children with mild ulcerative colitis (<a href="./references#CD005573-bbs2-0057" title="TurnerD , RuemmeleFM , Orlanski-MeyerE , GriffithsAM , deCarpiJM , BronskyJ , et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;62(2):257-91. [DOI: 10.1097/mpg.0000000000002035]">Turner 2018</a>), but not as a first‐line therapy, despite the findings and relatively low number needed to treat for an additional beneficial outcome (NNTB). Our review found evidence from one study supporting this recommendation, however, we consider it insufficient to draw conclusions on the use of probiotics as add‐on therapy. The current NICE guidelines do not recommend the use of probiotics in the conservative management of ulcerative colitis (<a href="./references#CD005573-bbs2-0048" title="National Institute for Health and Care Excellence. Ulcerative Colitis Mangagement in adults, children and Young people CG166. NICE2013. [https://www.nice.org.uk/guidance/ng130/evidence/june-2013-full-guideline-pdf-6777262190]">NICE 2013</a>). <a href="./references#CD005573-bbs2-0061" title="MallonPT , McKayD , KirkSJ , GardinerK . Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005573]">Mallon 2007</a> found that as a stand alone or combined therapy, probiotics led to no differences in remission rates. This was based on scant evidence from four studies. The results of the current review show that probiotics may improve remission in comparison with placebo. When combined with 5‐ASA it may slightly improve remission than 5‐ASA alone. Even though this is based on low‐certainty evidence, it changes the conclusion of the previous review, and in particular has specific implications for future research (see below). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005573-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD005573-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005573-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005573-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.2 Clinical remission: subgroup analysis by age." data-id="CD005573-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.2 Clinical remission: subgroup analysis by age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.10 Serious adverse events." data-id="CD005573-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.10 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 1: Clinical remission" data-id="CD005573-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 1: Clinical remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 2: Clinical remission: subgroup analysis by age" data-id="CD005573-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 2: Clinical remission: subgroup analysis by age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 3: Clinical remission: subgroup analysis by number of strains" data-id="CD005573-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 3: Clinical remission: subgroup analysis by number of strains </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 4: Histological remission" data-id="CD005573-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 4: Histological remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 5: Disease improvement" data-id="CD005573-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 5: Disease improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 6: Clinical activity scores" data-id="CD005573-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 6: Clinical activity scores</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 7: Histology scores" data-id="CD005573-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 7: Histology scores</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 8: Biochemical markers of inflammation" data-id="CD005573-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 8: Biochemical markers of inflammation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 9: Minor adverse events" data-id="CD005573-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 9: Minor adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 10: Serious adverse events" data-id="CD005573-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 10: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 11: Withdrawal due to adverse events" data-id="CD005573-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 11: Withdrawal due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 1: Clinical remission" data-id="CD005573-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 1: Clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 2: Clinical activity scores" data-id="CD005573-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 2: Clinical activity scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 3: Biochemical markers of inflammation" data-id="CD005573-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 3: Biochemical markers of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 4: Minor adverse events" data-id="CD005573-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 4: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 5: Serious adverse events" data-id="CD005573-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 5: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 6: Withdrawal due to adverse events" data-id="CD005573-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 6: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005573-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/urn:x-wiley:14651858:media:CD005573:CD005573-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 1: Remission (based on Sunderland disease activity index)" data-id="CD005573-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_t/tCD005573-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 1: Remission (based on Sunderland disease activity index) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/media/CDSR/CD005573/image_n/nCD005573-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005573-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to placebo for induction of remission in ulcerative colitis (follow‐up 2 to 52 weeks)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/>(1.19 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>594<br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was defined as the absence of rectal bleeding, a rectal mucosa without erythaema, granularity, or friability and normal or near‐normal sigmoidoscopic findings (<a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a>); clinical DAI ≤ 2 (<a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a>); occurrence or worsening of symptoms, accompanied by an increase in LCAI &gt; 3, sufficient to require treatment with corticosteroids, azathioprine/immunosuppressive agents or surgery (<a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>); final DAI score &lt; 2 (<a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a>); UCDAI scores of 0‐2 (<a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a>); UCDAI score &lt; 2 (<a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>); not having more than three well‐formed stools per day and without visible blood in the stools and any clinical symptoms of ulcerative colitis and had a clinical activity index &lt; 4 (<a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a>); remission was based on UCDAI, however, no further information was provided (<a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a>), bloody diarrhoea, without tachycardia, without fever, without anaemia and normal ESR and/or CRP (<a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>436 per 1000<br/>(300 to 640) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease improvement (based on clinical scores)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.29<br/>(1.13 to 4.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>54<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional RCT (144 participants) showed that probiotics improved disease based on endoscopic scores (RR 1.45, 95% CI 1.03 to 2.05). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>594 per 1000<br/>(249 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.42 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>520<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events reported were gastrointestinal disorders, unpleasant taste in the mouth, dizziness, flu‐like symptoms, acne, alopecia and dyspepsia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000<br/>(56 to 345) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.09<br/>(0.01 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>526<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Aggravated proctosigmoiditis was reported in the placebo group in one study as the only adverse event. No other study provided further details. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.42 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>401<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No study provided details on the adverse events leading to withdrawal from trial.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(66 to 268) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; CRP: c‐reactive protein; DAI; disease activity index; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; UCDAI: ulcerative colitis disease activity index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for high risk of bias in most of the studies and serious imprecision due to sparse data. We did not downgrade for inconsistency (substantial heterogeneity, I<sup>2</sup> = 66%) as effect estimates were fairly consistent across studies and heterogeneity was attributed to the differences in probiotic preparation.<br/><sup>2b</sup>Downgraded three times for risk of bias, very serious inconsistency (substantial heterogeneity, I<sup>2</sup> = 69%) and very serious imprecision due to CIs which include a risk of benefit and harm.<br/><sup>c</sup>Downgraded three times for risk of bias and very serious imprecision as CI includes a risk of benefit and harm.<br/><sup>d</sup>Downgraded two times for very serious imprecision as CI includes a risk of benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005573-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic compared to 5‐ASA for induction of remission in ulcerative colitis (52 weeks follow‐up; one study unclear)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospitals <br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.73 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was defined as general well‐being with the passage of no more than three formed stools per day, a rectal mucosa without erythaema, granularity or friability as well as histological confirmation. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>746 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000<br/>(544 to 865) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1,23</p> <p>(0.56 to 2.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>192<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor adverse events were abdominal pain, nausea, headache and mouth ulcer.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000 (63 to 395)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21</p> <p>(0.01 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events reported were perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> <p>(0 to 143)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21</p> <p>(0.01 to 4.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawals were due to perforated sigmoid diverticulum and respiratory failure in a patient with severe emphysema. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> <p>(0 to 143)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylates; <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for risk of other bias (participants were classified according to disease severity and given specific concomitant treatments based on this classification, this puts the randomisation into question) and serious imprecision due to small sample size in a single study.<br/><sup>b</sup> Downgraded two times for risk of other bias; (participants were classified according to disease severity and given specific concomitant treatments based on this classification, this puts the randomisation into question) and once due to serious imprecision due to low event numbers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005573-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics plus 5‐ASA compared to 5‐ASA for induction of remission in ulcerative colitis (follow‐up 4 weeks to 24 months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with active ulcerative colitis<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotic plus 5‐ASA<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic plus 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/>(1.01 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Remission was assessed based on the Sunderland activity score</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>930 per 1000<br/>(770 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times for unclear risk of bias in most domains and serious imprecision due to small sample size in a single study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005573-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table showing outcome data</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number induced</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Minor adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse events requiring withdrawal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0001" title="KatoK , MizunoS , UmesakiY , IshiiY , SugitaniM , ImaokaA , et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology &amp; Therapeutics2004;20(10):1133-41. ">Kato 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10 versus 3/10</p> <p>40% versus 33%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absence of rectal bleeding, a rectal mucosa without erythaema, granularity, or friability and normal or near‐normal sigmoidoscopic findings </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 versus 1/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0004" title="MatthesH , KrummernerlT , GienschM , WolffC , SchulzeJ . Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine2010;10:13. ">Matthes 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/70 versus 2/20</p> <p>49% versus 45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical DAI ≤ 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported on graph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/10 versus 10/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/70 versus 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/70 versus 3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0005" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/14 versus 4/15</p> <p>93% versus 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occurrence or worsening of symptoms, accompanied by an increase in LCAI &gt; 3, sufficient to require treatment with corticosteroids, azathioprine/immunosuppressive agents or surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 versus 0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 versus 0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0006" title="OliviaS , Di NardoG , AloiM , FalconieriP , FerrariF , MallardoS , et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition2011;52:E156. ">Oliva 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 versus 0/20</p> <p>25% versus 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final DAI score &lt; 2 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0007" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/57 versus 44/59</p> <p>66% versus 77%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General well‐being with the passage of no more than three formed stools per day, a rectal mucosa without erythaema, granularity or friability as well as histological confirmation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Mean)</p> <p>42 days versus 44 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/57 versus 7/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 versus 2/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 versus 2/59: unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0011" title="TamakiH , NakaseH , InoueS , KawanamiC , ItaniT , OhanaM , et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy2016;28(1):67-74. ">Tamaki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/28 versus 12/28</p> <p>54% versus 43%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI scores of 0‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28 versus 0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28 versus 0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28 versus 0/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0013" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences2017;69(1):24-8. ">Vejdani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/17 versus 13/17</p> <p>82% versus 76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient not having more than 3 well‐formed stools per day and without visible blood in the stools and any clinical symptoms of ulcerative colitis and had a clinical activity index &lt; 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Mean)</p> <p>25 days versus 32 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/17 versus 12/17:</p> <p>unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17 versus 0/17:</p> <p>unable to differentiate</p> <p>induction versus maintenance</p> <p>data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0012" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/71 versus 23/73</p> <p>44% versus 32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI score &lt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/71 versus 9/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/71 versus 0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0010" title="SoodA , MidhaV , MakhariaGK , AhujaV , SingalD , GoswamiP , et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology2009;7(22):1202-9. ">Sood 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/77 versus 11/70</p> <p>43% versus 16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCDAI scores not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/77 versus 0/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/77 versus 0/73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0003" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22:3344-8. ">Liu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/42 versus 32/42</p> <p>90% versus 76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on the Suntherland disease activity index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 versus 0/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0008" title="Sánchez-MoralesA , Pérez-AyalaMF , Cruz-MartínezM , Arenas-OsunaJ , Ramírez-MendozaP , CenicerosRA , et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/17 versus 0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical remission, considered in patient without bloody diarrhoea, without tachycardia, without fever, without anaemia and normal ESR and/or CRP (provided by author via email on 17/12/2019) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0009" title="SolovyevaO . Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:S221. ">Solovyeva 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0014" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD005573-bbs2-0002" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20, 0/20, 0/20</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Note: steroid withdrawal, biochemical markers of inflammation, histology scores, need for additional therapy, progression to surgery, clinical scores, and quality of life scores have not been reported in any of the studies. </p> <p>DAI: disease activity index; CRP: c‐reactive protein; ESR: erythrocyte sedimentation rate; LCAI: Lichtiger colitis activity index; UCDAI: ulcerative colitis activity index; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table showing outcome data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/full#CD005573-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005573-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clinical remission: subgroup analysis by age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Adult population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.07, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Paediatric population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [1.69, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical remission: subgroup analysis by number of strains <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Single strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.79, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Multiple strains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.31, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Histological remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.56, 11.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Disease improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Clinical improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.13, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Endoscopic improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.03, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Histological improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.09, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Clinical activity scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Histology scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Biochemical markers of inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 TNF‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 IL‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 IL‐1beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 IL‐8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.42, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.42, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005573-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Clinical activity scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.07 [‐3.22, ‐0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Biochemical markers of inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.16 [‐3.57, ‐2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Serum IL‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.47, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Serum IL‐8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐66.10 [‐71.63, ‐60.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 hs‐CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.03 [‐3.45, ‐2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.56, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005573-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Remission (based on Sunderland disease activity index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.01, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005573.pub3/references#CD005573-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005573.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005573-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005573-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005573-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005573-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD005573-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD005573-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD005573-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005573-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005573\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005573\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005573\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005573\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005573\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005573.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005573.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005573.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005573.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005573.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724619823"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005573.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724619827"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005573.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e67431c22f44a',t:'MTc0MDcyNDYyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 